Celgene buries the hatchet with India's Natco over generic Revlimid

Celgene ($CELG) is getting in the holiday spirit, settling its Revlimid patent fight with Indian generics maker Natco. Under the settlement, Celgene will let Natco roll out copycat versions of its $5 billion bestseller starting in 2022, as long as Natco agrees to a "volume-limit license." The license restricts the amount of capsules Natco can sell, giving Celgene some breathing room before Natco's full launch in 2026. More

Suggested Articles

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

NICE rejected Spravato over cost concerns and a lack of head-to-head clinical data against other NICE-recommended alternatives.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?